伴有低钠血症的心力衰竭治疗新药——托伐普坦

Tolvaptan:a novel agent for hyponatraemia in patients with heart failure

心力衰竭时常伴随低钠血症。心力衰竭的一般治疗方法对低钠血症疗效不佳。托伐普坦是精氨酸加压素V_2受体的拮抗药。托伐普坦通过抑制肾脏集合管水的重吸收,使肾脏对水的排泄增加,起到纠正低钠血症、增加尿量、改善心力衰竭症状等作用。临床研究表明托伐普坦在伴有低钠血症的心力衰竭治疗中发挥重要作用。

Hyponatraemia is often seen in association with heart failure. Traditional treatments for heart failure are less effective for hyponatraemia. Tolvaptan is a selective arginine vasopressin V2 receptor antagonist which inhibits collecting duct water reabsorption, promotes excretion of electrolyte-free water, and is effective in correcting hyponatraemia, increasing urine volume, improving heart failure symptom. The clinical studies showed that tolvaptan played an important role in the treatment of hyponatraemia in patients with heart failure.